Also found in: Dictionary, Wikipedia.
Related to capecitabine: Oxaliplatin


an oral antimetabolite used in treatment of metastatic breast or colorectal carcinoma; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Fluoropyrimidine, antimetabolite (pyrimidine analog)

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Box Warning

• In patients receiving concomitant oral coumarin-derivative anticoagulants (such as warfarin and phenprocoumon), monitor International Normalized Ratio (INR) or prothrombin time (PT) frequently to allow appropriate anticoagulant dosage adjustment. Altered coagulation parameters, bleeding, and death have occurred in patients taking this drug combination. Postmarketing reports show significant INR and PT increases in patients stabilized on anticoagulants when capecitabine therapy began. Age older than 60 and cancer diagnosis independently increase coagulopathy risk.


Enzymatically converts to 5-fluorouracil, which injures cells by interfering with DNA synthesis, cell division, RNA processing, and protein synthesis


Tablets: 150 mg, 500 mg

Indications and dosages

Metastatic breast cancer resistant to both paclitaxel and a chemotherapy regimen that includes anthracycline; metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred

Adults: Initially, 2,500 mg/m2/day P.O. in two divided doses for 2 weeks, followed by a 1-week rest period; administered in 3-week cycles

Dosage adjustment

• Renal impairment

• Hepatic impairment

• Elderly patients


• Hypersensitivity to drug

• Severe renal impairment

• Pregnancy or breastfeeding


Use cautiously in:

• mild to moderate renal impairment, hepatic impairment, severe diarrhea, coronary artery disease, intestinal disease, infection, coagulopathy

• children younger than age 18.


• Give with water within 30 minutes after a meal.

• If dosage must be lowered because of toxicity, don't increase dosage later.

Adverse reactions

CNS: dizziness, fatigue, headache, insomnia, paresthesia

CV: edema

EENT: eye irritation

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, stomatitis, intestinal obstruction

Hematologic: anemia, lymphopenia, neutropenia, thrombocytopenia

Metabolic: dehydration

Musculoskeletal: myalgia, limb pain

Skin: dermatitis, alopecia, nail disorder, hand and foot syndrome (palmarplantar erythrodysesthesia)

Other: fever


Drug-drug. Antacids: increased capecitabine blood level

Leucovorin: increased cytotoxicity

Live-virus vaccines: impaired ability to mount an immune response to vaccine

Phenytoin: increased phenytoin blood level

Warfarin: increased risk of bleeding

Drug-diagnostic tests. Bilirubin: increased level

Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

Patient monitoring

• Monitor patient for signs and symptoms of toxicity. Be prepared to reduce dosage or withhold drug when indicated.

• Stay alert for signs and symptoms of infection.

• Carefully assess fluid and electrolyte status if patient has severe diarrhea.

• Monitor weight, CBC, International Normalized Ratio, prothrombin time, and kidney and liver function test results.

• Evaluate closely for adverse reactions in patients older than age 80.

Patient teaching

• Advise patient to take drug with water within 30 minutes after a meal.

Instruct patient to immediately report nausea, vomiting, diarrhea, mouth ulcers, swollen joints, temperature above 100.5 °F (38 °C), and other signs or symptoms of infection.

• Tell patient to expect dosage adjustments during therapy.

• Urge patient to use reliable birth control method because drug may harm fetus if she becomes pregnant.

• Caution patient not to breastfeed during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A prodrug converted to 5-fluorouracil.
Farlex Partner Medical Dictionary © Farlex 2012


An antineoplastic drug that is converted into 5-fluorouracil in the body, used in the treatment of colorectal cancer and metastatic breast cancer.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


An anticancer drug used especially in treatment of cancers of the rectum or colon that have been found to have spread. The drug is noticeably less liable to produce undesirable side effects than other forms of anticancer chemotherapy. It is also used in the treatment of breast cancer with some success. A brand name is Xeloda.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
At CSCO, new data will be presented from ASLAN's phase 2A, single arm, multicenter study of varlitinib plus capecitabine in unselected Chinese patients with second line BTC.
The sNDA is supported by the results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb (lapatinib) plus capecitabine in patients with third-line HER2-positive metastatic breast cancer.
The US Food and Drug Administration (FDA) has received a supplemental new drug application (sNDA) from United States-based Puma Biotechnology for neratinib in combination with capecitabine intended for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease), it was reported yesterday.
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine lone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Novadoz Pharmaceuticals reported on Wednesday the receipt of approvals to market its first products, Rosuvastatin, Capecitabine and Moxifloxacin tablets.
Capecitabine tablets represent the latest addition to Aurobindo's broad line of vertically integrated generic pharmaceuticals.
This hypothesis is supported by the fact that the patient noticed significant improvement in respiratory symptoms within a few weeks of starting capecitabine and after an interval PET scan showed significant improvement in the diffuse uptake in the bone marrow.
We used 1500 mg/[m.sup.2] capecitabine and 200mg/[m.sup.2] temozolomide for treatment of our patients.
We describe a case of a patient who continued to progress during treatments with carboplatin, paclitaxel, melphalan, actinomycin D, and radiotherapy but achieved 18 months of progression free survival (PFS) and an improved quality of life with oral capecitabine despite her diffusely metastatic disease.
Experts carried out a largescale study to compare capecitabine with an alternative treatment known as CMF.
Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).
[8] studied the effects of preoperative metronomic combination of paclitaxel, Cyclophosphamide, and capecitabine (mPCX) followed by 5-fluorouracil (FU), epirubicin, and Cyclophosphamide (FEC) as preoperative chemotherapy in 40 TNBC patients.